Parallel Industries EAPH · USD

Its shares trade under the ticker EAPH. It has been listed since 29 September 2000. In the fiscal year to 31 December 2019, it reported revenue of $1.6m and a net loss of $323,171. At that date it held total assets of $17.2m and shareholders' equity of $7.1m.

Easton Pharmaceuticals, Inc. engages in the design, development, and marketing of drugs, therapeutic, and cosmetic healthcare products. The company is headquartered in North York, Ontario. The company went IPO on 2000-09-29. The firm has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The firm owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The firm's products are in various stages of commercialization. The firm's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.

Figures and description from our data supplier, not checked against the company's own report.

• John AdamsPresident, Chief Executive Officer
• Walter FolinskiChief Financial Officer, since 2013
• Neil MellorChief Operating Officer
• Dr. Jack BarkinSenior Vice President, Chief Medical Officer
• Susan WhyteVice President - Marketing
• John MitchellVice President - Business Development
• Mr. Luigi GentileDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.